Novogen (NASDAQ:KZIA) Earns “Buy” Rating from HC Wainwright

Novogen (NASDAQ:KZIA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 195.08% from the stock’s previous close.

Several other brokerages have also commented on KZIA. Maxim Group lifted their price objective on Novogen from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Wall Street Zen upgraded Novogen to a “hold” rating in a research note on Saturday, November 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Novogen Trading Down 7.0%

Shares of KZIA stock opened at $6.10 on Wednesday. The company has a 50 day moving average price of $8.83 and a 200-day moving average price of $8.19. Novogen has a 52 week low of $2.86 and a 52 week high of $17.40.

Novogen (NASDAQ:KZIA) last issued its earnings results on Friday, November 7th. The company reported ($6.14) earnings per share (EPS) for the quarter. The company had revenue of $0.59 million for the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.